Excessive underarm sweating: severity, region, and treatment options

When another cause may need to be checked

• Excessive underarm sweating that is not caused by another condition typically begins in adolescence or early adulthood. New-onset underarm sweating in mid-life or later — especially with night sweats, unexplained weight loss, fever, or recent medication changes — is much more likely to be secondary and deserves in-person medical evaluation before treating the sweating itself.
• On both sides of the body, symmetric, limited to certain areas sweating with stoppage during sleep points to the common area-specific pattern. Mainly on one side sweating, generalized sweating, or sweating that includes whole-body symptoms does not.

Common patterns and symptoms

• • Visible sweat marks on clothing in cool environments
• • Sweating that begins in adolescence and is symmetric on both sides
• • Daily clothing changes or wardrobe limitations driven by sweat
• • Sweating that stops during sleep (a hallmark of common area-specific pattern)
• • Yellow staining on light fabrics or odor concerns concentrated under the arms

How severity changes the usual order of options

The Excessive sweating Disease Severity Scale (HDSS) is the most useful instrument for next-step guidance in underarm disease. HDSS 1–2 typically anchors at antiperspirants applied to the skin — including aluminum chloride hexahydrate formulations — with prescription skin treatments that reduce sweating considered when over-the-counter products are not enough. HDSS 3–4 broadens the conversation to the full order of options: prescription skin treatments that reduce sweating, pills that reduce sweating, Botox injections, microwave thermolysis (miraDry), and the targeted alkali thermolysis patch (Brella). The HDSS questions are short and validated for treatment-response interpretation.

What is in the underarm order of options

Five evidence-supported tiers are typically considered for excessive underarm sweating. First, antiperspirants applied to the skin — both over-the-counter and prescription-strength aluminum chloride hexahydrate — remain first-line. Second, prescription skin treatments that reduce sweating include glycopyrronium tosylate (Qbrexza), FDA-approved for primary excessive underarm sweating in patients 9 years and older, and sofpironium topical gel (Sofdra), FDA-approved in the same population. Third, pills that reduce sweating like glycopyrrolate and oxybutynin are used off-label for excessive sweating when topicals are insufficient. Fourth, onabotulinumtoxinA injections are FDA-approved for underarm disease and deliver months of reduction with each treatment cycle. Fifth, in-office procedures: miraDry (microwave thermolysis) targets and destroys sweat glands in one to two sessions; the Brella SweatControl Patch is a recently FDA-cleared four-minute in-office procedure. Endoscopic thoracic sympathectomy (ETS) surgery exists in the literature but is rarely recommended for isolated underarm disease given less invasive options.

How Qbrexza and Sofdra differ

Both Qbrexza (glycopyrronium tosylate) and Sofdra (sofpironium) are once-daily prescription skin treatments that reduce sweating indicated for primary excessive underarm sweating in adults and pediatric patients 9 years and older. They differ in molecule, dosage form (cloth vs gel), main result measured in the clinical trials (ASDD vs HDSM-Ax-7), application instructions, and the specific side effects in their labels. A separate comparison page walks through the side-by-side trial data when cited evidence records resolve.

When underarm disease may not be area-specific

Several patterns suggest excessive sweating caused by a medicine or another health condition or a different diagnosis altogether: sweating that began suddenly in middle age, sweating that is mainly during sleep, sweating that involves the whole body rather than specific body areas, sweating that is limited to one side or mainly on one side, and sweating that begins after starting a new medication. Hormone-related disorders (hyperthyroidism, pheochromocytoma), infections, malignancies (particularly lymphoma), neurologic conditions, and many medications can produce sweating that looks superficially like excessive sweating but requires evaluation of the underlying cause.

Reading paths from here

If you have not yet used the HDSS calculator, start there to get a score-and-pathway snapshot. To compare Qbrexza and Sofdra side-by-side, see the comparison page. To read about a specific treatment, the treatments hub indexes all options with FDA status, evidence summaries, and reasons a treatment may not be safe. If any safety-next-step guidance flag applies to your situation, prioritize the safety pathway over treatment escalation.

Treatment options for this type of sweating

Frequently asked

Is excessive underarm sweating the same as just sweating a lot?

No. Excessive underarm sweating that is not caused by another condition is a chronic, on both sides of the body, symmetric pattern that typically begins in adolescence, stops during sleep, and interferes with daily activities. Most people sweat more in warm weather or during exercise without meeting the criteria for excessive sweating. The HDSS scale and the on both sides of the body / sleep-stoppage pattern are the best way to distinguish the condition from variation in normal sweating.

Will Qbrexza or Sofdra work for hand or foot sweating?

Both Qbrexza and Sofdra are FDA-approved only for excessive underarm sweating. Their pivotal trials studied underarm disease and their labels indicate underarm use. For hand or excessive foot sweating, the usual order of treatment options differs — iontophoresis enters the usual order of options earlier, and onabotulinumtoxinA is used off-label.

When is Botox a reasonable choice?

OnabotulinumtoxinA (Botox) is FDA-approved for primary excessive underarm sweating and is typically considered when skin treatments are not enough, when pills that reduce sweating are poorly tolerated, or when the patient prefers a periodic in-office treatment over daily product use. Injection effects last several months; treatment cycles are repeated as the effect wears off.

How is miraDry different from Brella?

miraDry uses microwave thermolysis to destroy sweat glands in the axilla, typically requiring one or two sessions for durable reduction. The Brella SweatControl Patch uses targeted alkali thermolysis, applied as a four-minute in-office procedure and repeated as needed. Both are FDA-cleared for underarm use and both differ from Botox in that they aim for longer-lasting reductions rather than periodic blockade. The full comparison is on the comparison page.

Reading paths

• Check your severity with the HDSS calculator →
• All hyperhidrosis treatments →
• Compare treatments →
• How Ecrina checks health claims →